261 related articles for article (PubMed ID: 32936899)
21. Pericytes Elicit Resistance to Vemurafenib and Sorafenib Therapy in Thyroid Carcinoma via the TSP-1/TGFβ1 Axis.
Prete A; Lo AS; Sadow PM; Bhasin SS; Antonello ZA; Vodopivec DM; Ullas S; Sims JN; Clohessy J; Dvorak AM; Sciuto T; Bhasin M; Murphy-Ullrich JE; Lawler J; Karumanchi SA; Nucera C
Clin Cancer Res; 2018 Dec; 24(23):6078-6097. PubMed ID: 30076136
[TBL] [Abstract][Full Text] [Related]
22. Co-inhibition of SMAD and MAPK signaling enhances 124I uptake in BRAF-mutant thyroid cancers.
Luckett KA; Cracchiolo JR; Krishnamoorthy GP; Leandro-Garcia LJ; Nagarajah J; Saqcena M; Lester R; Im SY; Zhao Z; Lowe SW; de Stanchina E; Sherman EJ; Ho AL; Leach SD; Knauf JA; Fagin JA
Endocr Relat Cancer; 2021 May; 28(6):391-402. PubMed ID: 33890869
[TBL] [Abstract][Full Text] [Related]
23. Inhibiting BRAF Oncogene-Mediated Radioresistance Effectively Radiosensitizes BRAF
Robb R; Yang L; Shen C; Wolfe AR; Webb A; Zhang X; Vedaie M; Saji M; Jhiang S; Ringel MD; Williams TM
Clin Cancer Res; 2019 Aug; 25(15):4749-4760. PubMed ID: 31097454
[TBL] [Abstract][Full Text] [Related]
24. Bortezomib sensitizes thyroid cancer to BRAF inhibitor
Tsumagari K; Abd Elmageed ZY; Sholl AB; Green EA; Sobti S; Khan AR; Kandil A; Murad F; Friedlander P; Boulares AH; Kandil E
Endocr Relat Cancer; 2018 Jan; 25(1):99-109. PubMed ID: 29269566
[TBL] [Abstract][Full Text] [Related]
25. Pharmacological inhibition of Ref-1 enhances the therapeutic sensitivity of papillary thyroid carcinoma to vemurafenib.
Hu L; Zhang J; Tian M; Kang N; Xu G; Zhi J; Ruan X; Hou X; Zhang W; Yi J; Ma W; Chang L; Tang T; Zheng X; Wei X; Gao M
Cell Death Dis; 2022 Feb; 13(2):124. PubMed ID: 35136031
[TBL] [Abstract][Full Text] [Related]
26. Long-term vemurafenib treatment drives inhibitor resistance through a spontaneous KRAS G12D mutation in a BRAF V600E papillary thyroid carcinoma model.
Danysh BP; Rieger EY; Sinha DK; Evers CV; Cote GJ; Cabanillas ME; Hofmann MC
Oncotarget; 2016 May; 7(21):30907-23. PubMed ID: 27127178
[TBL] [Abstract][Full Text] [Related]
27. IL6/STAT3 axis mediates resistance to BRAF inhibitors in thyroid carcinoma cells.
Notarangelo T; Sisinni L; Trino S; Calice G; Simeon V; Landriscina M
Cancer Lett; 2018 Oct; 433():147-155. PubMed ID: 29969659
[TBL] [Abstract][Full Text] [Related]
28. Acquired Secondary RAS Mutation in BRAF
Cabanillas ME; Dadu R; Iyer P; Wanland KB; Busaidy NL; Ying A; Gule-Monroe M; Wang JR; Zafereo M; Hofmann MC
Thyroid; 2020 Sep; 30(9):1288-1296. PubMed ID: 32216548
[No Abstract] [Full Text] [Related]
29. Lenvatinib Targets PDGFR-β Pericytes and Inhibits Synergy With Thyroid Carcinoma Cells: Novel Translational Insights.
Iesato A; Li S; Roti G; Hacker MR; Fischer AH; Nucera C
J Clin Endocrinol Metab; 2021 Nov; 106(12):3569-3590. PubMed ID: 34302727
[TBL] [Abstract][Full Text] [Related]
30. Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation.
Chakravarty D; Santos E; Ryder M; Knauf JA; Liao XH; West BL; Bollag G; Kolesnick R; Thin TH; Rosen N; Zanzonico P; Larson SM; Refetoff S; Ghossein R; Fagin JA
J Clin Invest; 2011 Dec; 121(12):4700-11. PubMed ID: 22105174
[TBL] [Abstract][Full Text] [Related]
31. HER inhibitor promotes BRAF/MEK inhibitor-induced redifferentiation in papillary thyroid cancer harboring BRAFV600E.
Cheng L; Jin Y; Liu M; Ruan M; Chen L
Oncotarget; 2017 Mar; 8(12):19843-19854. PubMed ID: 28423638
[TBL] [Abstract][Full Text] [Related]
32. BRAFV600E mutation, TIMP-1 upregulation, and NF-κB activation: closing the loop on the papillary thyroid cancer trilogy.
Bommarito A; Richiusa P; Carissimi E; Pizzolanti G; Rodolico V; Zito G; Criscimanna A; Di Blasi F; Pitrone M; Zerilli M; Amato MC; Spinelli G; Carina V; Modica G; Latteri MA; Galluzzo A; Giordano C
Endocr Relat Cancer; 2011 Dec; 18(6):669-85. PubMed ID: 21903858
[TBL] [Abstract][Full Text] [Related]
33. Down-regulation of the human major histocompatibility complex class I chain-related gene A (MICA) and its receptor is mediated by microRNA-146b-5p and is a potential mechanism of immunoediting in papillary thyroid carcinoma.
Al-Abdallah A; Jahanbani I; Mehdawi H; Ali RH; Al-Brahim N; Mojiminiyi O; Junaid TA
Exp Mol Pathol; 2020 Apr; 113():104379. PubMed ID: 31935378
[TBL] [Abstract][Full Text] [Related]
34. Analysis of the Role of FRMD5 in the Biology of Papillary Thyroid Carcinoma.
Gaweł AM; Ratajczak M; Gajda E; Grzanka M; Paziewska A; Cieślicka M; Kulecka M; Oczko-Wojciechowska M; Godlewska M
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34201607
[TBL] [Abstract][Full Text] [Related]
35. Pin1 inhibitor API-1 sensitizes BRAF-mutant thyroid cancers to BRAF inhibitors by attenuating HER3-mediated feedback activation of MAPK/ERK and PI3K/AKT pathways.
Dang H; Sui M; He Q; Xie J; Liu Y; Hou P; Ji M
Int J Biol Macromol; 2023 Sep; 248():125867. PubMed ID: 37473892
[TBL] [Abstract][Full Text] [Related]
36. Genetic and pharmacological targeting of CSF-1/CSF-1R inhibits tumor-associated macrophages and impairs BRAF-induced thyroid cancer progression.
Ryder M; Gild M; Hohl TM; Pamer E; Knauf J; Ghossein R; Joyce JA; Fagin JA
PLoS One; 2013; 8(1):e54302. PubMed ID: 23372702
[TBL] [Abstract][Full Text] [Related]
37. Association between diffuse lymphocytic infiltration and papillary thyroid cancer aggressiveness according to the presence of thyroid peroxidase antibody and BRAF
Lee YK; Park KH; Park SH; Kim KJ; Shin DY; Nam KH; Chung WY; Lee EJ
Head Neck; 2018 Oct; 40(10):2271-2279. PubMed ID: 29935011
[TBL] [Abstract][Full Text] [Related]
38. Elevated BANCR expression levels have different effects on papillary thyroid carcinoma progression depending on the presence of the BRAFV600E mutation.
Stojanović S; Šelemetjev S; Đorić I; Rončević J; Janković Miljuš J; Živaljević V; Išić Denčić T
Eur J Surg Oncol; 2020 Oct; 46(10 Pt A):1835-1842. PubMed ID: 32651027
[TBL] [Abstract][Full Text] [Related]
39. IL-17A increases MHC class I expression and promotes T cell activation in papillary thyroid cancer patients with coexistent Hashimoto's thyroiditis.
Han LT; Hu JQ; Ma B; Wen D; Zhang TT; Lu ZW; Wei WJ; Wang YL; Wang Y; Liao T; Ji QH
Diagn Pathol; 2019 Jun; 14(1):52. PubMed ID: 31159823
[TBL] [Abstract][Full Text] [Related]
40. Identification of a Recurrent LMO7-BRAF Fusion in Papillary Thyroid Carcinoma.
He H; Li W; Yan P; Bundschuh R; Killian JA; Labanowska J; Brock P; Shen R; Heerema NA; de la Chapelle A
Thyroid; 2018 Jun; 28(6):748-754. PubMed ID: 29768105
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
